Emergent BioSolutions Inc. (EBS) stock intrinsic value fair value estimate & owner earnings analysis

Emergent BioSolutions sells two kinds of products. The larger is medical countermeasures for biological threats, sold mostly to the U.S. government's Strategic National Stockpile and to foreign governments: ACAM2000 smallpox and mpox vaccine, VIGIV and TEMBEXA for smallpox, BioThrax and CYFENDUS anthrax vaccines, ANTHRASIL, BAT botulism antitoxin and Ebanga for Ebola. Many of these are the only licensed product of their kind, and the U.S. government bought them in every year of the decade we reviewed. In 2025 this side earned $456.7 million of revenue (smallpox $266.1 million, anthrax $114.3 million, other $76.3 million). The second is naloxone for opioid overdose, mainly NARCAN nasal spray. Its sales fell 43% to $226.1 million in 2025 as generics cut both price and volume. Total 2025 revenue was $742.9 million. The U.S. government accounted for 46% of it. The company has changed a great deal. It earned heavily from COVID-19 contract manufacturing in 2020-2021, lost large sums in 2022-2023, then in 2023-2025 sold its travel-health vaccines, RSDL and its Camden and Bayview plants, and cut costs sharply. We therefore measure normal earning power only from 2024-2025, the years that reflect the business as it now stands. Owner earnings (operating cash flow excluding working-capital swings, less stock compensation and the capital spending needed to maintain the business) were $87.8 million ($1.66 a share) in 2024 and $163.0 million ($2.87) in 2025. The midpoint is about $2.27 a share, or roughly $118 million. Both years were flattered by one-time items: a $50 million arbitration settlement from Janssen in 2024 and a $10.5 million litigation reimbursement in 2025. Accounting judgements: in 2024 we treated the write-off of the old Janssen manufacturing asset as a non-cash charge, not a working-capital release. We added back about $65 million a year of amortization on acquired product rights, because that cost is already sunk. We accounted for the decline of those rights directly in the forecast instead, by letting NARCAN fade. Recent results push the starting point well below that midpoint. In the second quarter of 2026 the company wrote down its NARCAN business by $191.3 million, citing weaker pricing and volumes in public-interest channels. It also cut its 2026 revenue outlook to $645-675 million from $720-760 million. First-half 2026 operating cash flow was $22.3 million, against $95.2 million a year earlier. Owner earnings grew 86% in 2025. Our base case nevertheless starts year one at about $68 million, a decline of roughly 59%, because the naloxone erosion shows up in two years of results and in the write-down. Debt is the second key issue. Borrowings total about $590 million: a $150 million term loan and $439.7 million of 3.875% notes due August 2028. Cash was $139.7 million at June 30, 2026. The company's most recent secured loan (2024) was priced at SOFR plus 8.25%, so refinancing the cheap 2028 notes will very likely raise interest costs substantially. Base case, $8.71 a share: The stockpile business holds roughly steady for five years. It is supported by contracts already in place: ACAM2000 options under the 2019 ten-year contract, the 10-year BAT contract worth up to $550 million (with a $64.5 million modification in 2026), the Department of War BioThrax contract running to September 2028 with an option to 2033, and the BARDA Ebanga contract worth up to $704 million over 10 years. The business then shrinks about 2% a year through year 10 and 3% a year after that, reflecting the steady fall in ACAM2000 order sizes ($120.0 million in 2023, $99.9 million in 2024, $56.0 million in 2025). Naloxone profits fade to nearly nothing within about ten years. Costs fall as the naloxone business shrinks, as they did when selling and administrative costs dropped 40% in 2025. The 2028 notes are refinanced at about 10% after some cash is used to pay debt down, and half of each year's cash goes to reducing debt. Owner earnings run about $68-85 million a year for the first five years, about $63 million by year 10, and about $45-50 million a year after that. We end the story in year 20 because no evidence reaches further. Bull case, $27.90 a share: Smallpox demand keeps building: smallpox sales rose 72% in the first half of 2026, ACAM2000 gained an mpox approval in August 2024, and TEMBEXA, BAT and Ebanga orders keep growing. Stockpile profits grow about 3% a year for five years and 2% a year to year 10, then hold level. Naloxone declines more slowly, helped by KLOXXADO. Costs keep falling. The notes are refinanced at about 9% and debt is fully repaid in about seven years. Owner earnings reach about $160 million a year by year 8 and hold near $150 million through year 25. Bear case, -$2.65 a share: The U.S. government lets the ACAM2000 contract lapse after its final option years around 2028 and does not replace it. It skipped an option year once before, in 2022. Anthrax and other stockpile orders decline 4-5% a year, naloxone profit is gone by about 2031, and costs fall only slowly. The 2028 notes are refinanced at about 12%, in line with the 2024 term loan. On that path the business's cash flows are worth about $310 million, against roughly $590 million of debt and $140 million of cash. The company would owe about $140 million more than it is worth, and shareholders would likely be wiped out in a restructuring. We value this case against the debt directly, because a business losing money after interest would not keep running unchanged for a decade. All cash flows are discounted at 6%. The range is very wide because a small number of government purchasing decisions and a single refinancing drive the outcome. Our value would be too high if U.S. stockpile purchases fall faster than ACAM2000's recent trend, or if refinancing costs well above 10%. It would be too low if the 2026 smallpox strength proves lasting. The per-share figures assume about 52 million shares; lender warrants and the company's share-sale program could add to that. One item could not be fully reconciled: 2025 operating cash flow of $170.6 million sits above what product margins, operating costs, interest and taxes imply (about $110-120 million), and part of the gap may come from asset-sale and milestone gains. The 2024-2025 midpoint therefore likely overstates recurring earnings, which is one reason the base case starts lower.